Compare Acadia Healthcare Company Inc (ACHC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Acadia Healthcare Company Inc vs Merck & Co., Inc. — how do they compare? Acadia Healthcare Company Inc trades at $31.81 (market cap $2.90B), while Merck & Co., Inc. trades at $133.44 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 111× Acadia Healthcare Company Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Acadia Healthcare Company Inc pays none. Which is the better fit depends on your goals.
| ACHC | MRK | |
|---|---|---|
Market Cap | $2.90B | $321.77B |
Sector | Health | Health |
52-Week High | $35.61 | $131.84 |
52-Week Low | $11.68 | $77.60 |
Enterprise Value | $5.29B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.85, up 0.22% today, with a neutral technical signal and bullish moving averages. The company reported Q2 2026 EPS of $0.38, beating estimates, but maintains negative net income margins near -33%. Revenue is stable at $3.3B, while analyst consensus is a Buy with a $36 price target. Recent news highlights ongoing litigation and operational progress.
Outlook is mixed: strong analyst support and earnings beats suggest upside, but profitability challenges and legal investigations pose significant risks. The stock's valuation appears reasonable with a P/E of 19.82, yet negative ROE and net income require careful monitoring for turnaround execution.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Acadia Healthcare Company Inc
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
